Rabeprazole and psychiatric symptoms

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1315-1317

  Polimeni, Giovanni ^a,e   Cutroneo, Paola ^b   Gallo, Adele ^c   Gallo, Salvatore ^d   Spina, Edoardo ^b   Caputi, Achille P ^b  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Department of Pharmacy   (Italy)

^d Department of Internal Medicine   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

Author keywords

Anxiety; Hypergastrinaemia; Panic disorder; Rabeprazole

Indexed keywords

ESOMEPRAZOLE; GASTRIN; GASTRIN RELEASING PEPTIDE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AGED; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; DEMENTIA; DEPRESSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HUMAN; HYPERGASTRINEMIA; MENTAL DISEASE; NARANJO PROBABILITY SCALE; NIGHTMARE; PANIC; PRIORITY JOURNAL; RATING SCALE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; FEMALE; HUMANS; MENTAL DISORDERS; MIDDLE AGED;

EID: 34547152689     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K134     Document Type: Article

References (18)

1. Product information. Aciphex (rabeprazole). Tokyo: Eisai Co., Ltd., revised August 2003.
2. Alfonzo CA, Bobo WV, Almond MD. Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report. Int J Psychiatry Med 2003;33:311-5.
3. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78.
4. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000;6: S491-505.
5. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
6. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994;8:39-46.
7. Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994;8:309-14.
8. Delchier JC, Benamouzig R, Stanescu L, et al. Twenty-four hour intragastric acidity and serum gastrin during 3-month treatment with omeprazole in healthy subjects. Aliment Pharmacol Ther 1997;11:747-53.
9. Takehara Y, Sumii K, Tari A, et al. Evidence that endogenous GRP in rat stomach mediates omeprazole-induced hypergastrinemia. Am J Physiol 1996;271:G799-804.
10. Yeomans ND, Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment Pharmacol Ther 2000;14:267-71.
11. Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000;14:15-22.
12. Roesler R, Henriques JA, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets 2006;5:197-204.
13. Bastaki SM, Hasan MY, Chandranath SI, Schmassmann A, Garner A. PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity. Mol Cell Biochem 2003;252:83-90.
14. McCann UD, Slate SO, Geraci M, Uhde TW. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers. Anxiety 1994-1995;1:258-67.
15. Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD. Pentagastrin-induced sleep panic attacks: panic in the absence of elevated baseline arousal. Biol Psychiatry 2002;52:1183-9.
16. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and serum gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-89.
17. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002;16:1301-7.
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.